Long-term compliance with lipid-lowering medication after genetic screening for familial hypercholesterolemia

Archives of Internal Medicine

Volumn 163, Issue 1, 2003, Pages 65-68

  Umans Eckenhausen, Marina A W ^a   Defesche, Joep C ^b   Van Dam, Marjel J ^b   Kastelein, John J P ^a  

^a F Ident Pers Inherited Hyperchol   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADOLESCENT; ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; DISEASE PREDISPOSITION; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; GENETIC SCREENING; HUMAN; MAJOR CLINICAL STUDY; MALE; NETHERLANDS; PATIENT ATTITUDE; PATIENT COMPLIANCE; PATIENT EDUCATION; PRIORITY JOURNAL;

ADULT; AGED; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; FEMALE; FOLLOW-UP STUDIES; GENETIC SCREENING; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; MALE; MIDDLE AGED; NETHERLANDS; PATIENT COMPLIANCE; QUESTIONNAIRES; SELF ADMINISTRATION; TIME FACTORS; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 0037434078     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.163.1.65     Document Type: Article

References (20)

1. Goldstein JL, Hobbs HH, Brown MS. Familial hypercholesterolemia. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic and Molecular Basis of Inherited Disease. 6th ed. New York, NY: McGraw-Hill Book Co; 1995:1981-2030.
2. Gould AL, Rossouw JE, Santanello NC, Heyse JF, Furberg CD. Cholesterol reduction yields clinical benefit: impact of statin trials. Circulation. 1998;97:946-952.
3. Scientific Steering Committee on behalf of the Simon Broome Register Group. Mortality in treated heterozygous familial hypercholesterolemia: implications for clinical management. Atherosclerosis. 1999;142:105-112.
4. Kane JP, Malloy MJ, Ports TA, Phillips NR, Diehl JC, Havel RJ. Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. JAMA. 1990;264:3007-3012.
5. Smilde TJ, van Wissen S, Wollersheim H, Trip MD, Kastelein JJP, Stalenhoef AFH. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. Lancet. 2001;357:577-581.
6. Umans-Eckenhausen MAW, Defesche JC, Sijbrands EJG, Scheerder RLJM, Kastelein JJP. Review of first 5 years of screening for familial hypercholesterolaemia in the Netherlands. Lancet. 2001;357:165-168.
7. Schectman G, Hiatt J. Drug therapy for hypercholesterolemia in patients with cardiovascular disease: factors limiting achievement of lipid goals. Am J Med. 1996;100:197-204.
8. Defesche JC. Familial hypercholesterolaemia. In: Betteridge DJ, ed. Lipids and Vascular Disease. London, England: Martin Dunitz; 2000:65-76.
9. Bhatnagar D, Morgan J, Siddiq S, Mackness MI, Miller JP, Durrington PN. Outcome of case finding among relatives of patients with known heterozygous familial hypercholesterolaemia. BMJ. 2000;321:1497-1500.
10. Kastelein JJP. Screening for familial hypercholesterolaemia: effective, safe treatments and DNA testing make screening attractive. BMJ. 2000;321:1483-1484.
11. Neil HAW, Hammond T, Huxley R, Matthews DR, Humphries SE. Extent of underdiagnosis of familial hypercholesterolaemia in routine practice: prospective registry study. BMJ. 2000;321:148.
12. West of Scotland Coronary Prevention Study Group. Baseline risk factors and their association with outcome in the West of Scotland Coronary Prevention Study. Am J Cardiol. 1997;79:756-762.
13. Pedersen TR, Olsson AG, Faergeman O, et al. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). Circulation. 1998;97:1453-1460.
14. Pyörälä K, De Backer G, Graham I, Poole-Wilson PA, Wood D. Prevention of coronary heart disease in clinical practice: recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Eur Heart J. 1994;15:1300-1331.
15. Wood D, De Backer G, Faergeman O, Graham I, Mancia G, Pyörälä K. Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. Eur Heart J. 1998;19:1434-1503.
16. Broadstock M, Michie S, Marteau T. Psychological consequences of predictive genetic testing: a systematic review. Eur J Hum Genet. 2000;10:731-738.
17. Grosfeld FJM. Beyond a Shadow of Doubt: Assessing the Psychological Impact of Predictive Genetic Testing for Multiple Endocrine Neoplasia Type II [thesis]. Utrecht, the Netherlands: University of Utrecht; 2000.
18. Levenkron JC, Loader S, Rowley PT. Carrier screening for cystic fibrosis: test acceptance and one year follow-up. Am J Med Genet. 1997;73:378-386.
19. Wake SA, Rogers CJ, Colley PW, Hieatt EA, Jenner CF, Turner GM. Cystic fibrosis carrier screening in two New South Wales country towns. Med J Aust. 1996; 164:471-474.
20. Marteau TM, Lerman C. Genetic risk and behavioural change. BMJ. 2001;322: 1056-1059.